AntibodyLimited DatastalePartner Therapeutics, Inc.Phase 2
MCLA-128 (zenocutuzumab, zenocutuzumab (MCLA-128))
Solid Tumours Harboring NRG1 Fusion; NSCLC Harboring NRG1 Fusion · Solid Tumours Harboring NRG1 Fusion
#SolidTumoursHarboringNRG1Fusion#Antibody#Phase2#monoclonal-antibody#NSCLCHarboringNRG1Fusion+1
Trials 1Status Recruiting